Icid(g)- meclo 3 column

Activity of Meclocycline Sulfosalicylate Tested
ICID 2006
Against Oral Pathogens
JMI Laboratories, North Liberty, Iowa, USA
¥ Meclocycline SS was markedly superior to ¥ Anaerobes (Table 2) were very susceptible to meclocycline SS with 23 of 27 strains inhibited Background: Meclocycline sulfosalicylate (MSS) is a topically-used
streptococci by inhibiting 96.3, 100.0 and tetracycline derivative that has been utilized for acne vulgaris treatments and for its other antimicrobial qualities for over three decades.
100.0% of viridans group streptococci, group Tetracycline-class agents also have non-antimicrobial features that can A and groups C/G streptococci, respectively minimize the release of free radicals, reduce expression of cytokines ¥ Table 3 shows the variable effects of tet and alter degeneration of vascular/connective tissues.
resistance mechanisms on the MICs of five Methods: Over 20 pathogen groups (265 strains) were tested, including
tetracyclines and a glycylcycline, tigecycline.
35 staphylococci (15 methicillin-resistant), 10 ¥ Essentially all tetracyclines were comparable group streptococci (8 species), 20 §-haemolytic streptococci, 30 to tetracycline HCl against Enterobacteriaceae MIC population distribution of four tetracyclines tested against Acinetobacters, 11 Burkholderia cepacia, 10 Moraxella catarrhalis, 10 Neisseria spp., and 27 anaerobic oral flora (10 species). Susceptibility tests were performed by reference CLSI methods (M7-A7, 2006) with Antimicrobial Agent ²0.016 0.03 0.06 0.12 ¥ Meclocycline SS had the best activity versus associated interpretive criteria (M100-S16, 2006). Comparison tetracyclines (four), tigecycline and six other drugs (data not shown) P. aeruginosa (80% inhibited at 4 mg/L) and were used. A MSS breakpoint concentration of ²4 mg/L was applied for comparisons only, that breakpoint most used for other tetracyclines.
Strains with documented tet-mechanisms of resistance were also tested.
Listing of tetracycline and glycylcycline class agent MIC results tested against S. aureus (5) and E. coli (7) strains with characterized Results: MSS exhibited equal or greater potency (MIC
to other tetracyclines against streptococci (0.03-0.25 mg/L), staphylococci ¥ B. cepacia was refractory to all tetracyclines, (0.06-0.12), Neisseria (0.06), most Enterobacteriaceae (1-2 mg/L) and Tetracycline Doxycycline Minocycline Oxytetracycline Tigecycline but upper airway colonizers/pathogens such some non-fermentative bacilli (Acinetobacter spp., MIC50 0.5 mg/L). P. aeruginosa and enterococci were inhibited by MSS with MIC M. catarrhalis and various Neisseria spp.
at 8-16 mg/L. MSS exhibited cross-resistance with other class agents tet A-E, K-M, O and S mechanisms. Generally, MSS was less potent than minocycline and tigecycline versus resistant Activity of five tetracycline antimicrobial agents tested against 226 recent clinical isolates by reference methodsa.
Conclusions: At concentrations topically utilized of this non-absorbed
tetracycline (MSS), the vast majority of the tested bacteria were inhibited, S. aureus, various streptococci and streptococci (MIC50, 0.03-0.25 mg/L), M. I N T R O D U C T I O N
(MIC50, 0.06 mg/L), and Neisseria spp.
Meclocycline sulfosalicylate (SS) is a topically applied tetracycline derivative that has been utilized for acne vulgaris treatment and for its other antimicrobial qualities for over three decades. Tetracycline-class agents also have non- antimicrobial features that can minimize the release of free radicals, reduce ¥ By testing strains possessing tet expression of cytokines and alter degeneration of vascular/connective tissues. To assess the continuing spectrum of meclocycline SS and older peer drugs (doxycycline, minocycline, oxytetracycline and tetracycline HCl), considered refractory to the antimicrobial all were tested against a wide variety of contemporary pathogens and upper airway or oral flora. Reference methods were utilized with commonly applied action of other tetracyclines would also be M AT E R I A L S A N D M E T H O D S
The susceptibility testing methods were reference procedures from the tetracycline derivatives tested, appears to Clinical and Laboratory Standards Institute (CLSI) documents M7-A7 (2006) and M11-A6 (2004). MIC interpretations followed CLSI M100-S16 (2006), where available. For comparison purposes, ²4 mg/L was the breakpoint for susceptibility applied to all tetracycline derivatives.
in its class, and appears appropriate for Organisms tested (n = 265) were generally recent clinical isolates or index use against pathogens associated with oral type strains from the American Type Culture Collection (ATCC). These mucositis by virtue of its anti-inflammatory included: S. aureus (25; 10 oxacillin-resistant [MRSA]), S. epidermidis (10; E. faecalis (10), viridans group streptococci (80; 8 species), S. pyogenes (10), serogroups C and G §-haemolytic streptococci (10), Enterobacteriaceae (30; 3 species), P. aeruginosa (10), A. baumannii B. cepacia (11), M. catarrhalis (10), Neisseria spp. (10; 5 species) and 27 anaerobic isolates (Tables 1 and 2). Also, a collection of 12 strains of A C K N O W L E D G E M E N T S
S. aureus or E. coli having well characterized tetracycline resistance We are thankful to the following individuals for the contribution of the bacterial strains used in the anaerobe component of this protocol: R. Darveau and P. Braham (University of Washington Department of Pediatrics); D. Drake and B. Olson (University of Iowa Department of Endodontics); D. Snydman and L. McDermott (Tufts University School of Medicine); and P. Bradford ¥ Meclocycline SS and minocycline were the most active tetracyclines tested against the R E F E R E N C E S
Clinical and Laboratory Standards Institute. (2006). Performance standards for antimicrobial susceptibility testing, 16th informational supplement M100- at ²4 mg/L of the tetracyclines, best for Clinical and Laboratory Standards Institute. (2006). Methods for dilution Criteria as published by the CLSI [2006], where available. A breakpoint of ²4 mg/L for susceptibility was applied to all tetracyclines for antimicrobial susceptibility tests for bacteria that grow aerobically, 7th ed. Approved Standard M7-A7. Wayne, PA: CLSI, 2006.

Source: http://www.jmilabs.com/data/posters/ICID2006/69-017.pdf


20 décembre 2007 N° 15 Le mot du Président Vous avez été nombreux à faire confiance à votre président et à soutenir les instances dirigeantesde l’Epaulette pour mener à bien des projets partagés, pour notre association. Ces derniers mois,beaucoup d’entre vous se sont investis à fond en vue d’atteindre l’objectif de recrutement dontL’Epaulette a besoin pour montrer sa


THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION. If you are in any doubt about the contents of this document and/or the action you should take, you should immediately consult your stockbroker, bank manager, solicitor or other independent financial advisor duly authorised under the Financial Services and Markets Act 2000 (as amended). TRICOR PLC (incorporated and regi

Copyright © 2010-2014 Medical Articles